The story of how a biotech co. came to the aid of an ill 9-year-old boy – Stockhouse

Nine years old. All of a boy. Pale in complexion with short brown hair, Cal’s hazel eyes smile beyond his predicament.

Running out of his classroom to his beloved music room, Cal was engrossed in his thoughts of playing Mozart’s Minuet in G Major perfectly for Miss Smith.

STOP his brain screamed! As he stopped to catch his breath, barely 40 feet from his classroom, Cal needed oxygen.

Defensively switching to a cheerful smile to cope with the classmates who ran by, Cal weaved to the wall, untangling his puffer from the ear buds in his pocket. The inhaler worked. Cal caught a breath as the medication permeated his lungs. Cal’s body continuously yearned the oxygen his lungs failed to produce. With his chest tightening relieved temporarily, Cal walked, then rested and walked the last 400 feet to the music room.

Misdiagnosed four times with asthma, Cal finally, the day before, learned he needed a heart and lung transplant. He was terminally ill. With Cal at her side, the Doctors at MSU gave his Mom the bad news: Cal had idiopathic pulmonary hypertension and a congenital heart defect. With a heart/lung transplant, he was given five to seven years to live. Unfortunately, without it, his lung condition would worsen very rapidly.

Cal struggled to remember the exact term the doctor used to describe his condition. Idiopathic, he remembered. Ruminating for the term, Cal greeted Miss Smith with a smile and a hello!”as he stepped into the classroom and sat at the piano. Idiopathic pulmonary hypertension,” Cal blurted unconsciously aloud. Pardon me,” asked Miss Smith? Cal shrugged his shoulders and smiled as he turned to Miss Smith: Mozart Minuet in G Major, Miss Smith,” he said.

Just then, Cal flashed the look on the doctor’s face when he told him that he had an inoperable hole in his heart, too. Inoperable because his lung pressure was three times normal. That explained the tightness in his chest.

Composed. Cal closed his eyes, smiled to himself, opened his eyes and started playing Mozart’s Minuet in G Major on the piano, perfectly.

Six days later, Cal’s Mom found ACP-01 online. Was it the answer to her prayers? It certainly seemed promising.

Two appointments later with Dr. G, Cal was told his own stem cells converted into angiogenic cell precursors (ACP) by Hemostemix (TSX-V:HEM, OTC: HMTFX, Forum) could treat his lung condition and perhaps reverse it. Dr. G explained his options: 1. Cal could wait and hopefully be eligible for a heart/lung transplant, if a donor match could be found in time. Or, 2. Immediately, Cal could use his own stem cells to regenerate lung function in a week. If it worked, he would regain lung function he thought was lost forever.

Looking at his Mom, Cal saw could read her face Finally, Cal, I think our prayers may be answered.”

Within two months of the procedure, Cal’s lung pressures decreased 50% and stabilized. Within three months, Cal's heart repair surgery was a go! Verified by imaging, following ACP-01 treatment, Cal’s heart was remodelling itself back to its normal size.

Cal has since lived nine years without medication and one year, the 10th since his procedure, with medication. Cal will undergo a second ACP-01 treatment shortly.

A true story, Cal is one of 500 hundred compassionate care patients who have been treated with their own stem cells processed into ACP-01. Like nearly 80% of recipients, Cal regained a quality of life he thought was lost forever.

In our view, given the Company’s current valuation ($7,600,000), Hemostemix represents one of the best biotech risk reward investments on the market.

For more information, Contact: Thomas Smeenk, Co-Founder, President & CEO 905-580-4170

FULL DISCLOSURE: Hemostemix Inc. is a client of Stockhouse Publishing.

Read more:
The story of how a biotech co. came to the aid of an ill 9-year-old boy - Stockhouse

Related Post